No Data
No Data
Meinong Biotechnology (301156.SZ): Cumulative repurchased 0.94% of shares.
On August 1st, GeLongHui reported that as of July 31st, 2024, the company has repurchased a total of 1,361,865 shares through a stock repurchase dedicated securities account using the centralized bidding trading method, accounting for 0.94% of the company's current share capital. The highest fill price was 16.69 yuan/share, the lowest fill price was 14.26 yuan/share, and the total transaction amount was 21,290,339.5 yuan (excluding transaction fees). This share repurchase is in compliance with the company's established share repurchase plan and relevant laws and regulations.
Shanghai Menon Animal Nutrition Technology Co., Ltd.'s (SZSE:301156) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Meinong Biology (301156.SZ): Specializing in R&D, production and sales of feed additives and enzymolysis protein feed ingredients
Gelonghui, May 21丨Meinong Biotech (301156.SZ) said on the investor interactive platform that the company specializes in R&D, production and sales of feed additives and enzymolysis protein feed ingredients. The company always adheres to the business philosophy of “technology drives value, innovation drives development”, implements the customer value proposition of “product leadership, value service, partner growth”, and implements a “centralized differentiation” development strategy. At the product level, adhere to the product strategy of “classification and full nutrition”; at the market level, adhere to the market strategy of “deeply cultivating the domestic market and expanding overseas markets”, and continuously enhance the company's core competition with multiple strategies
Meinong Biotech (301156.SZ): It has now established a sales network in Brazil and other countries and regions
Gelonghui, May 14, 丨 Meinong Biotech (301156.SZ) recently said during a survey reception from institutional investors that the company has always been committed to exploring and developing the international market, and has laid a good foundation for the international market for more than 20 years. At present, the company has established sales networks in various countries and regions such as Vietnam, Russia, Thailand, Myanmar, the Philippines, Japan, South Korea, Pakistan, Bangladesh, Egypt, Jordan, Turkey, and Brazil. The company's future development plan for overseas business: (1) Following the country's “Belt and Road” policy, the company will focus on developing the Southeast Asian market, South Asia and the Middle East market. (2) At
Meinong Biotech (301156.SZ) plans to transfer 10 shares to 3 shares and distribute 5.5 yuan, excluding interest on May 13
Zhitong Finance App News, Meinong Biotech (301156.SZ) announced that the company's 2023 equity distribution plan: 5.5 yuan (tax included) for every 10 shares to all shareholders; at the same time, 3 shares will be transferred to all shareholders for every 10 shares. The ex-dividend date is May 13, 2024.
Meinong Biotech (301156.SZ): Net profit of 9.58 million yuan in the first quarter increased 0.47% year-on-year
On April 24, Gelonghui Biotech (301156.SZ) released its first quarter report. Operating revenue was 97.906 million yuan, up 7.57% year on year, net profit of 9.58 million yuan, up 0.47% year on year, after deducting non-net profit of 8.979 million yuan, down 2.49% year on year, with basic earnings of 0.0856 yuan per share.
No Data